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0022-2836/$ - see front matter © 2007 EThe bifunctional protein U5-52K is associated with the spliceosomal 20 S U5
snRNP, and it also plays a role in immune response as CD2 receptor binding
protein 2 (CD2BP2). U5-52K binds to the CD2 receptor via its GYF-domain
specifically recognizing a proline-rich motif on the cytoplasmic surface of
the receptor. The GYF-domain is also mediating the interaction of the
proteins U5-52K and U5-15K within the spliceosomal U5 snRNP. Here we
report the crystal structure of the complex of GYF-domain and U5-15K
protein revealing the structural basis for the bifunctionality of the U5-52K
protein. The complex structure unveils novel interaction sites on both
proteins, as neither the polyproline-binding site of the GYF-domain nor the
common ligand-binding cleft of thioredoxin-like proteins, to which U5-15K
belongs, are involved in the interaction of U5-15K and U5-52K.
© 2007 Elsevier Ltd. All rights reserved.Keywords: U5 snRNP; pre-mRNA splicing; crystal structure; bifunctionality;
CD2-receptor binding protein*Corresponding authorThe “one protein - one structure - one function”
paradigm has become outdated due to an increasing
number of bi- and multi-functional proteins parti-
cipating in many diverse cellular processes.1,2 Bi-
functional proteins are also involved in the splicing
of pre-mRNA in the nucleus of eukaryotic cells as
recently shown for the U5 snRNP-specific 52K pro-
tein, which is identical to the CD2 receptor binding
protein 2 (CD2BP2).3 The U5 snRNP is a major
component of the spliceosome generally formed by
the five snRNPs U1, U2, U4, U5, U6 and several
non-snRNP proteins.4,5 The human 20 S U5 snRNP
consists of the uracil-rich U5 snRNA, seven Sm
proteins that are common to all UsnRNPs with the
exception of U6, and the U5 particle-specific
proteins 15K, 40K, 52K, 100K, 102K, 110K, 116K,
200K and 220K,6–8 which mediate important steps
during assembly, maturation and dissociation of the
spliceosome.5 The U5 snRNP assembles with the
U4/U6 snRNP and the resulting U4/U6.U5 tri-
snRNP joins U1 and U2 snRNPs and other proteins
forming the pre-spliceosome leading to the activetario Cancer institute,
1, Toronto, Ontario,
ng author:
lsevier Ltd. All rights reservespliceosome. During these assembly processes sev-
eral proteins having fulfilled their function are
leaving the complex.9 The U5-52K protein belongs
to this group, as it is thought to dissociate from the
U5 snRNP during assembly of the U4/U6.U5 tri-
snRNP. Purified U5 snRNP from Saccharomyces
cerevisiae also contains the U5-52K protein (SNU40/
Lin1p), suggesting a conserved role in pre-mRNA
splicing.10 U5-52K associates with the U5 snRNP by
binding to the U5-15K protein,3 an evolutionarily
highly conserved component of the U5 and U4/U6.
U5 snRNPs.11 This interaction is mediated by the
C-terminal domain of U5-52K,3 which is also
required for the interaction of U5-52K/CD2BP2
with the CD2 receptor.12,13
The CD2 receptor is located on the surface of T
cells, thymocytes and natural killer cells, and
interacts with CD2BP2 through two proline-rich
motifs located in the cytoplasmic tail of CD2.12 Over-
expression of a CD2-binding U5-52kD fragment
significantly enhances the production of interleukin
2, indicating a functional role of U5-52K/CD2BP2 in
immune response reactions.12 The NMR structure of
the C-terminal 86 amino acid residues of CD2BP2,
which are capable of binding to CD2, revealed a
novel polyproline interacting domain, denoted as
the GYF-domain.13 The structure of the GYF-domain
with a bound peptide, that contains the cognate pro-
line-rich PPPPGHR sequence present in CD2, hasd.
Notes to Table 1:
Recombinant human U5-15K protein and the GYF-domain of
U5-52K were purified as described.3,11 The His-tag of the GYF-
domain was cleaved by thrombin at 4 °C overnight. The proteins
were mixed in equimolar ratio and the complex was allowed to
form overnight at 4 °C. The complex was purified by gel filtration
chromatography (Superdex75-26/60, Amersham Biosciences)
using buffer A (20 mM Tris-HCl (pH 7.8), 120 mM NaCl, 2 mM
DTT, 1 mM EDTA). The complex crystallized as plate bundles in
14% (w/v) PEG2000 MME, 100 mM Mes (pH 6.5), 100 mM
calcium acetate, 4% (v/v) 1,4 butanediol at 4 °C.
X-ray diffraction data were collected at the EMBL beam line
X13 (DESY, Hamburg) to a resolution of 2.35 Å. The data were
903U5 snRNP-specific Binary Protein Complex Structurealso been determined by NMR,14 revealing a novel
binding mode for a polyproline motif. In contrast to
the SH3 domain, which has two hydrophobic
binding pockets, the GYF-domain contains one
deep binding pocket.
The GYF-domain of U5-52K/CD2BP2 was shown
also to mediate the interaction of the U5-52K and
U5-15K proteins within the U5 snRNP. However,
U5-15K lacks the cognate proline-rich motif, raising
the question about the molecular basis for this
specific protein–protein interaction. The previously
determined crystal structure of the U5-15K revealed
a thioredoxin-like fold that is characterized by a
four-stranded β-sheet consisting of pairs of parallel
and antiparallel strands flanked by three α-helices.11
Compared to thioredoxin the U5-15K contains
additional 37 residues, of which 22 residues extend-
ing the C terminus were proposed to form a putative
interaction site.11,15
In order to understand the molecular details and
specificity of the interaction between the U5-15K
and the U5-52K proteins, we have determined the
crystal structure of the complex of full-length
U5-15K and the GYF-domain of U5-52K revealing
novel interaction sites for both proteins.
Complex preparation and structure
determination
The human U5-15K protein and the GYF-domain
of the human U5-52K protein were prepared
separately and the binary protein complex was
obtained by in vitro reconstitution. Gel-filtration
chromatography of this complex revealed an appar-
ent molecular mass of 25 kDa, indicating a 1:1 molarTable 1. Data collection and refinement statistics
Data collection
Resolution range (Å) 50–2.35
No. of unique reflections 30,397
No. of observed reflections 72,742
Completeness (%)
Overall 92.4




Last shell (Å) 18.4 (2.41–2.35)
I/σ(I)
Overall 20.9
Last shell (Å) 2.4 (2.41–2.35)
Refinement statistics
Resolution range (Å) 50–2.35
R-factorb (%)
Overall 21.6
Last shell (Å) 28.0 (2.39–2.35)
R-freeb (%),
Overall 26.2
Last shell (Å) 31.0 (2.39–2.35)
Deviation from ideal geometry
Bond lengths (Å) 0.008




92.8/6.6/0.6ratio of both proteins in the complex (data not
shown). Crystals of the purified complex were
obtained at a temperature of 4 °C. The crystals be-
long to space group C2 and contain three hetero-
dimeric complexes in the asymmetric unit. The
crystallographic phase problem was solved by
means of molecular replacement and the crystal
structure was refined to a resolution of 2.35 Å with a
final R-free value of 26.2% (Table 1). The structures
of the U5-15K and GYF-domain are well defined in
the electron density map except for some flexible
regions in the C and/or N termini. The refined
model of the U5-15K present in the complex consists
of amino acid residues 3–137. The structure of the
GYF-domain of U5-52K (residues 256–341) lacks the
N-terminal 24 residues due to conformational
flexibility. The three copies of each of both proteins
present in the asymmetric unit are almost identical.
The rmsd values of corresponding superimposed
main chain atoms are small (<0.6 Å), and the fewprocessed with DENZO and SCALEPACK (HKL Research, USA).
Crystals contain three U5-52K-GYF-15K complexes in the asym-
metric unit, corresponding to a Matthews coefficient of
2.6 Å3/Da22 and a solvent content of 53%.
The structure was determined by molecular replacement
using the program MOLREP from the CCP4 program package.23
The U5-15K protein (PDB code: 1QGV) and the GYF-domain
(PDB code: 1GYF) were used as search models. The most
representative NMR structure of the GYF-domain (out of the 16
available) was calculated on the OLDERADO server.24 The model
was refined with CNS25 using simulated annealing, individual
B-factor refinement and positional refinement. The model was
visualized andmanually corrected with the programO.26 The last
refinement step was a TLS refinement in REFMAC.23 The quality
of the final model was validatedwith the program PROCHECK.23
The total buried surface area upon complex formation was
calculated with the program areaimol and the shape comple-
mentarity coefficient (sc) was calculated with SC; both programs
are from the CCP4 program package.23 Figures were made in
PYMOL (DeLano, W.L. The PyMOL Molecular Graphics System
(2002) DeLano Scientific, USA). The electrostatic potential was
calculated by the Poisson-Boltzmann equation as implemented in
the program DelPhi27 and visualized with PYMOL.
a Rsym=100·∑|I– (I)|2/∑|I|2, where I is the observed
intensity and (I) is the average intensity for multiple
measurements.
b R-factor=100·∑|Fo – Fc|/∑|Fo|, where Fo and Fc are the
observed and calculated structure factors, respectively. R-free is
the cross-validation R factor calculated for 10% of the reflections
omitted in the refinement process.
c Calculated with PROCHECK.
904 U5 snRNP-specific Binary Protein Complex Structureobserved differences concern side-chain conforma-
tions mostly caused by different crystal contacts.
The overall complex structure
The binary complex comprising U5-15K and the
GYF-domain of U5-52K exhibits an elongated overall
shape with the dimensions 50 Å×25 Å×25 Å (Figure
1). U5-15K consists of a five-stranded β-sheet
surrounded by four α-helices, and the GYF-domain
contains an antiparallel β-sheet flanked by three α-
helices. The interaction surface of U5-15K resides
within the 22 C-terminal residues Glu111–Ser132.
These residues interact with residues Lys321–Thr341
at the C terminus of the GYF-domain (Figure 2). The
description of residues mediating the interaction of
the two proteins is restricted to those, which are
consistent for all three complexes present in the
asymmetric unit. The GYF-domain and the U5-15K
protein are bound mainly by polar interactions
(Figure 2(b)) including salt-bridges between Glu111,
OE1 (U5-15K) and Gln328, NE2 (U5-52K), hydrogen
bonds between side-chains of Asp114, OD2, Glu117,
OE2 and Ser132, OG (U5-15K) and side-chains of
Tyr330, OH, Lys321, NZ and Arg334, NH2 (U5-52K)
and between main chains Ser132, O (U5-15K) and
side-chains Arg334, NE (U5-52K). Finally, there is a
hydrogen bond between the side-chain of Lys125, NZ
(U5-15K) and the C-terminal oxygen of Thr341 (U5-
52K). CD1 and CD2 from residue Leu339 (U5-52K)
are forming hydrophobic contacts to CG2 of Val130
and CA of Gly122 (U5-15K).Figure 1. Cartoon representation of the U5-15K:U5-52K co
Cys79 are shown in ball-and-stick mode. The GYF domain of U
and Phe313 are displayed in ball-and-stick mode.The total surface areas buried upon complex
formation for the three complexes in the asymmetric
unit are 1328 Å2, 1290 Å2 and 1310 Å2, which gives
an average value of 1309 Å2. Inspection of the crystal
packing reveals that, besides the contact within each
complex, both proteins are mainly in contact with
their respective symmetry mates, as U5-15K pro-
teins pack against other U5-15K proteins and like-
wise the GYF-domains are in contact with other
GYF-domains. There is only one crystal contact be-
tween a U5-15K protein and a GYF-domain mole-
cule belonging to a different complex in the unit cell.
The corresponding total buried surface area for this
contact between U5-15K and GYF-domain is only
90 Å2. The value of the total buried surface area
together with the shape complementarity coefficient
of the functional complex (average for the three
complex molecules in the asymmetric unit was
calculated to be 0.700) correlate well with values
suggested by Lawrence et al.,16 which strongly
supports that the complex shown in Figure 1 indeed
is the biologically functional complex.
The U5-15K and GYF-domain structures
Superimposing the previously determined struc-
tures of the individual proteins onto the complex
structure reveals that the overall conformation of
each protein does not change upon complex
formation (Figure 3), nevertheless there are some
subtle changes. Residues 96–101 of U5-15K, which
are missing in the crystal structure of U5-15K,11 aremplex. U5-15K is shown in cyan and dark blue. Cys38 and
5-52K is shown in light magenta and pink. Gly311, Tyr312
Figure 2. Interactions between the two proteins. (a) Surface representation colored according to the electrostatic
potential. The surface complementarity between the two molecules is clearly seen in the open complex. The residues
involved in the direct interaction are labeled. (b) A stereo picture of the polar interactions and the distances between the
interacting atoms. U5-15K is shown in orange and U5-52K in blue. The interactions are found in all three molecules.
905U5 snRNP-specific Binary Protein Complex Structurewell defined in the electron density of the com-
plex due to stabilization through crystal contacts
(Figure 3(a)). Residues 72–77 of U5-15K have a
different conformation in the complex, where the
location of Tyr73–Leu75 is shifted in the directionof the C terminus. Cys38 and Cys79, which are
capable of forming a disulfide bridge, are in the
reduced state. These cysteine residues have earlier
been shown to have no functional impact for the
U5-15K protein.11
Figure 3. Stereo representations of the superposition
of the two components of the complex structure with the
uncomplexed structures. The structures of the two
proteins in the complex are shown in blue, whereas the
uncomplexed structures are depicted in magenta. (a) The
superposition of complexed 15K and uncomplexed 15K
(PDB code: 1QGV). The main differences are found in the
termini of the protein, which is most likely due to
flexibility. (b) The superposition of the 52K proteins from
the complex and from the NMR structure (PDB code:
1GYF).
906 U5 snRNP-specific Binary Protein Complex StructureThe structure of the GYF-domain of U5-52K in
the complex is also almost identical to the structure
of the uncomplexed GYF-domain (Figure 3(b)) when
compared with the most representative NMR struc-
ture. It consists of an antiparallel β-sheet followed
by an α-helix. As observed in the NMR structure of
the GYF-domain alone,13 the crystal structure of
the complex lacks the N-terminal 24 residues due
to conformational flexibility and disorder in the
crystal.
A novel protein–protein interaction site for a
thioredoxin-like protein
The interaction between the U5-15K protein and
the GYF-domain of U5-52K involves regions onboth protein surfaces not expected by the previous
structural studies on both proteins. Indeed, the
structure of the U5-15K-GYF-domain complex
reveals a new interaction site for thioredoxin-like
proteins. Among the few known complex structures
of thioredoxin or thioredoxin-like proteins the
interaction with other proteins mostly involves the
cleft close to the redox-active disulfide bridge.17–19
The complex between phosducin that contains a C-
terminal thioredoxin-like domain, and transducin
βγ20 shares some similarities with the U5-15K-GYF-
domain complex with respect to the thioredoxin
part of the complex interface. However, the exten-
sion of the phosducin compared to thioredoxin is
more comprehensive than in the U5-15K and the
involved residues are also found further towards
the C terminus. This example and the U5-15K-GYF
complex suggest that different extensions of the
thioredoxin fold have been adapted in order to
generate novel specific functions of thioredoxin-like
proteins that do not involve the redox-active
disulfide bridge of thioredoxin.Structural basis for the bifunctionality of U5-52K
The two known cellular functions of U5-52K
comprise the binding to either the CD2 receptor or
the spliceosomal U5-15K protein. These two inter-
actions involve clearly separated binding sites on
the GYF-domain (Figure 4). The GYF-domain of
U5-52K is capable of specifically binding proline-
rich sequences (PPPPGHR) of other proteins,13 but
it does not bind the U5-15K through its polypro-
line-binding site. This raises the question whether
the different cellular functions of U5-52K are
strictly related to its two separated protein-binding
sites. Recently, it has been shown that the GYF-
domain is capable of interacting with the spliceo-
somal SmB and SmB' proteins by binding a less
proline-rich sequence (+/GxxPPGx+).21 However,
the physiological significance of this binding has to
be clarified, as the SmB/B' proteins are common to
the snRNPs U1, U2, U4, U5, but the 52K protein is
exclusively associated with the U5 snRNP due to
its interaction with U5-15K and another U5 specific
protein, the U5-102K.3
The sequence alignments (Supplementary Data,
Figure 1) of orthologs of the U5-15K protein and the
GYF-domain, respectively, further show that the
U5-15K is significantly more highly conserved than
U5-52K. This indicates that the U5-52K protein has
been adjusted to different cellular functions in di-
verse organisms.
U5-52K is an interesting example of a bifunctional
protein, which acts in immune response and also
plays a role in the spliceosomal machinery. The basal
function of the U5-52K appears to be related to the
splicing process, as U5-52K is found in the spliceo-
somal U5 snRNPs from yeast to human. The other
function of U5-52K as CD2-binding protein, how-
ever, is restricted to mammals due to the occurrence
of T-cell-specific receptors.
Figure 4. Separated binding sites on the GYF-domain. The GYF-domain is shown in a surface representation either in
complex with (a) the U5-15K protein, or (b) a proline-rich peptide. The interaction with the U5-15K protein and the
polyproline motif of the CD2 receptor involves two clearly separated binding sites on the GYF-domain.
907U5 snRNP-specific Binary Protein Complex StructureProtein Data Bank accession code
The coordinates of the complex and the structure
factors have been deposited in the RCSB Protein Data
Bank and are available under accession code 1SYX.
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